Betamethasone
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Betamethasone: Alopecia mucinosa
One-Sentence Summary
Betamethasone is a potent corticosteroid with anti-inflammatory and immunosuppressive activity. The TxGNN model predicts it may be effective for alopecia mucinosa, but there are 0 clinical trials and only 1 publication (a 1964 case series) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this report. Betamethasone belongs to the glucocorticoid class, whose members suppress inflammatory signalling and immune cell activity.
Alopecia mucinosa (follicular mucinosis) involves perifollicular inflammation and mucin deposition in hair follicles. An anti-inflammatory corticosteroid is therefore a plausible fit mechanistically. However, the link rests on general pharmacological reasoning. The only supporting publication is a 1964 case series, and no modern data exist.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14164963 | 1964 | Case series | Archives of dermatology | Report of three cases of follicular mucinosis (alopecia mucinosa) with a review of therapy. No abstract is available, and the report does not provide modern efficacy data for betamethasone. |
India Market Information
At least 20 valid single-ingredient licences are recorded, and the list may be partial. Licence records carry no approved-indication text. Main authorizations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 26850 | Besole 0.5mg Tablet | Strip of 10 tablets | Not stated in the licence record |
| 27072 | Betnevin 4mg Injection | Vial of 1 ml injection | Not stated in the licence record |
| 139463 | Mycopar Cream | Tube of 5 gm cream | Not stated in the licence record |
| 38129 | Celestone 0.5mg Oral Drops | Bottle of 10 ml oral drops | Not stated in the licence record |
| 25777 | Betnesol Oral Drops | Packet of 15 ml oral drops | Not stated in the licence record |
Other formulations on the market include ointments and oral drops.
Safety Considerations
- Drug Interactions: 451 interactions are recorded. Examples include adalimumab (Major), and zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen and ethinylestradiol (all Moderate).
- Conditions of concern: Betamethasone has recorded contraindication relations with hypertension, congestive heart failure, hyperglycemia, epilepsy, herpes simplex virus keratitis, measles, and several pituitary hormone deficiency disorders. These are not taken from label text.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but the only evidence is a 1964 case series with no trials and no modern data. No cited study directly shows betamethasone efficacy in alopecia mucinosa, so the evidence is too weak to support advancing. By the evidence rules, the level should therefore be treated as L5 (model prediction only); the L4 shown above comes from the dataset’s own scoring and should be downgraded on review.
To proceed, the following is needed:
- Controlled or at least modern observational studies of corticosteroids in follicular mucinosis
- Detailed mechanism of action data
- Package insert warnings and contraindications from the local regulator
- A safety plan covering the interaction and contraindication findings above, especially for long-term or systemic use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.